List of Excipients in Branded Drug DYE-FREE CHILDRENS LORATADINE

Generic Drugs Containing DYE-FREE CHILDRENS LORATADINE

Company	Ingredient	NDC	Excipient
UP & UP	loratadine	11673-111	ANHYDROUS CITRIC ACID
UP & UP	loratadine	11673-111	ASPARTAME
UP & UP	loratadine	11673-111	CELLULOSE, MICROCRYSTALLINE
UP & UP	loratadine	11673-111	MAGNESIUM STEARATE
UP & UP	loratadine	11673-111	MANNITOL
UP & UP	loratadine	11673-111	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in DYE-FREE CHILDRENS LORATADINE?

# Of NDCs	Excipient
16	ANHYDROUS CITRIC ACID
16	ASPARTAME
16	CELLULOSE, MICROCRYSTALLINE
16	MAGNESIUM STEARATE
16	MANNITOL
16	SILICON DIOXIDE

Dye-Free Children’s Loratadine: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Dye-free children’s loratadine is a low-barrier OTC formulation opportunity centered on tolerability, label simplicity, and retail differentiation rather than molecule-level exclusivity. Loratadine is a mature antihistamine with broad generic availability, so commercial performance depends on dosage form, taste, dosing accuracy, excipient selection, packaging, and channel execution.

The strongest product concept is an oral liquid for children age 2 years and older that combines dye-free labeling with one or more additional attributes: sugar-free, alcohol-free, accurate dosing, pleasant flavor, recyclable packaging, or preservative minimization. The principal technical challenge is maintaining loratadine solubility and physical stability while limiting excipients that may concern parents, pharmacists, or regulators.

What is dye-free children’s loratadine?

Dye-free children’s loratadine is an oral pediatric formulation of loratadine that excludes synthetic color additives. It is generally positioned for temporary relief of allergy symptoms, including sneezing, runny nose, itchy or watery eyes, and itching of the nose or throat.

Loratadine is a second-generation H1 antihistamine. It is practically insoluble in water, which makes liquid formulation more complex than tablet manufacturing. A commercial liquid requires a solvent system, solubilization strategy, pH control, flavor system, preservative strategy, and packaging configuration that support dose uniformity and shelf life.

The product should not be confused with desloratadine, loratadine’s active metabolite. Desloratadine is a separate active ingredient with a separate regulatory and patent history.

What excipients are needed in a children’s loratadine oral liquid?

A dye-free liquid typically requires excipients from six functional categories.

Excipient function	Typical options	Commercial and technical purpose
Vehicle	Purified water	Primary liquid carrier
Solubilization	Propylene glycol, polyethylene glycol, polysorbates, other surfactant systems	Improves loratadine dissolution and prevents precipitation
Sweetening	Sucrose, sorbitol, sucralose, acesulfame potassium, other approved sweeteners	Masks bitterness and improves adherence
Buffering and pH control	Citric acid, sodium citrate, phosphate systems	Controls chemical stability, taste, and preservative performance
Preservation	Sodium benzoate, potassium sorbate, other suitable preservatives	Controls microbial growth in multidose packaging
Flavoring	Fruit or berry flavors, natural or artificial flavor systems	Improves pediatric acceptability

The final excipient system must be established through formulation development and regulatory review. An excipient that is acceptable in one concentration or dosage form may create a different safety or labeling issue in another.

Why solubility is the key formulation problem

Loratadine’s low aqueous solubility creates the largest development risk. Simply increasing sweetness or flavor will not solve precipitation. A formulation developer must select a solvent and surfactant system that produces a clear or acceptably uniform liquid across the intended temperature range.

The development program should test:

• Loratadine concentration at the target dose volume.
• Precipitation after dilution with water or juice.
• Freeze-thaw and elevated-temperature stability.
• pH drift during storage.
• Compatibility with high-density polyethylene or polyethylene terephthalate bottles.
• Adsorption to dosing syringes, cups, caps, and bottle liners.
• Uniformity of dose after storage and repeated shaking.
• Flavor changes caused by pH, preservatives, and solvent levels.

The formulation should not rely on a single excipient to solve both solubility and taste. High levels of cosolvents may produce an unpleasant mouthfeel, while surfactants may introduce bitterness or foaming.

Which dye-free excipients create the strongest commercial positioning?

Dye-free is valuable but is rarely sufficient as a standalone differentiator. The strongest positioning usually combines dye-free status with attributes that address common parent and pharmacist concerns.

Dye-free and sugar-free

A dye-free, sugar-free liquid can target parents seeking reduced sugar exposure or products suitable for children with dietary restrictions. Sorbitol and high-intensity sweeteners can support this positioning, but sugar alcohols may cause gastrointestinal discomfort at sufficient intake. The product label should provide clear information on sweeteners and serving size.

Dye-free and alcohol-free

Alcohol-free positioning may improve acceptance among parents and pediatric healthcare professionals. The product must still achieve adequate solubility and microbiological control without ethanol. This can increase reliance on glycols, surfactants, pH adjustment, and preservatives.

Dye-free with a calibrated dosing syringe

An oral syringe can create more practical value than a cup, particularly for younger children and small dose volumes. The syringe should be compatible with the bottle closure and should deliver the labeled volume consistently.

Dye-free and preservative-minimized

A preservative-free multidose oral liquid is technically difficult because repeated opening creates microbial contamination risk. This opportunity is more realistic through unit-dose packaging, specialized dispensing systems, or a dry powder for reconstitution. Those formats may increase manufacturing and packaging costs.

What pediatric safety issues affect excipient selection?

Pediatric excipient selection requires exposure-based assessment rather than simple ingredient avoidance. The relevant variables include age, body weight, maximum daily dose, dosing frequency, duration of use, and the concentration of each excipient.

Important review areas include:

• Propylene glycol exposure in younger children.
• Sorbitol-related gastrointestinal effects.
• Sodium content in children requiring sodium restriction.
• Preservative exposure during repeated dosing.
• Potential allergen declarations for flavoring materials.
• Dental exposure from sugars or fermentable carbohydrates.
• Ethanol content, if any.
• Polyethylene glycol or surfactant tolerability.
• Microbial control in multidose packaging.

The FDA Inactive Ingredient Database provides a reference point for excipients previously used in approved drug products, but database presence does not automatically establish suitability for every pediatric concentration or route of administration. Formulators must evaluate the proposed exposure and product-specific safety profile. The FDA has also published pediatric-focused guidance on inactive ingredients and excipient exposure assessment.[1,2]

A dye-free claim does not mean the product is free of all substances that may concern consumers. Flavoring agents, preservatives, sweeteners, and solvent systems remain relevant to the label and marketing strategy.

What FDA regulatory pathway applies to children’s loratadine?

Loratadine is regulated in the United States as an OTC antihistamine. The applicable OTC framework includes the antihistamine monograph requirements in 21 C.F.R. Part 341, subject to current FDA rules and product-specific compliance obligations.[3]

A manufacturer may commercialize a compliant product under the OTC monograph pathway if the formulation, active ingredient, concentration, labeling, dosage, indications, warnings, and manufacturing controls meet the applicable requirements. A product that falls outside the monograph may require an approved drug application or another FDA pathway.

The principal regulatory workstreams are:

1. Confirming the active ingredient and concentration.
2. Establishing the eligible pediatric age range.
3. Validating the dose-measuring device.
4. Supporting finished-product stability.
5. Demonstrating microbial quality.
6. Establishing container-closure integrity.
7. Ensuring Drug Facts labeling compliance.
8. Supporting all inactive ingredients and color claims.
9. Confirming current registration, listing, and manufacturing obligations.

A dye-free claim should be supported by the formulation composition and manufacturing controls. The product should not contain color additives through the active ingredient, excipient system, flavor, coating, printing, or processing aids in a way that makes the claim misleading.

What is the Orange Book status of loratadine?

The Orange Book is principally relevant to approved prescription and certain approved nonprescription drug products. It does not function as a complete patent database for all OTC loratadine products.

Loratadine’s original prescription-era exclusivity and core compound patent protection have expired. The market is therefore dominated by generic and private-label products. Any current protection is more likely to involve a particular formulation, delivery system, packaging configuration, manufacturing process, trademark, or trade secret than the loratadine molecule itself.

Protection category	Relevance to dye-free children’s loratadine
Core loratadine compound patent	Generally expired; not a meaningful barrier to ordinary generic entry
Basic oral liquid formulation	Likely difficult to protect broadly if disclosed or previously used
Specific excipient ratios	May support narrower formulation claims if novel and non-obvious
Preservative or stability system	Potentially protectable when tied to unexpected stability or compatibility results
Unit-dose or dispensing system	May create device or packaging claims
Flavor system	More often protected through trade secrets and supplier agreements
Brand name and trade dress	Protectable through trademark and unfair-competition law
Manufacturing process	Potential patent or trade-secret value
Pediatric labeling	Regulatory compliance issue, not usually a durable exclusivity right

A product-specific freedom-to-operate conclusion cannot be drawn without a defined formulation, manufacturer, jurisdiction, and launch date.

What patents protect dye-free children’s loratadine?

The highest-value patent opportunities would relate to a specific technical solution rather than the general concept of removing dyes.

Potential claim categories include:

• A stable aqueous loratadine solution with defined solvent concentrations.
• A formulation that prevents precipitation after dilution.
• A low-surfactant or surfactant-free solubilization system.
• A preservative system with defined pH and excipient ratios.
• A taste-masked composition with a defined flavor and sweetener combination.
• A unit-dose package that maintains sterility or microbial quality.
• A reconstitutable powder with improved loratadine dispersion.
• A dosing device configured for a specific concentration or bottle closure.
• A manufacturing process that improves content uniformity or reduces degradation.

Broad claims covering a “dye-free loratadine liquid” would face substantial validity and prior-art risk. A stronger patent strategy would link the dye-free formulation to measurable technical effects, such as improved stability, reduced precipitation, lower preservative concentration, better taste scores, or improved dose uniformity.

When does loratadine lose exclusivity?

Loratadine has already lost the exclusivity associated with its original branded prescription market. Claritin, originally associated with Schering-Plough, became widely available as a generic and OTC product after the expiration of its primary exclusivity barriers.

There is no biosimilar pathway for loratadine because it is a chemically synthesized small molecule, not a biologic. Competitive risk comes from generic tablets, orally disintegrating tablets, chewables, oral liquids, private-label products, and competing antihistamines such as cetirizine, levocetirizine, and fexofenadine.

What generic entry risks exist for dye-free children’s loratadine?

Generic entry risk is high at the active-ingredient level. A competitor can usually enter with a different excipient system if it meets applicable FDA requirements.

The most likely competitive scenarios are:

Launch scenario	Competitive effect
Store-brand dye-free liquid	Direct price pressure and retailer substitution
Sugar-free dye-free liquid	Higher-value segmentation
Chewable or orally disintegrating product	Reduces dependence on liquid formulation
Single-dose packets	Appeals to travel, school, and convenience channels
Combination allergy product	Expands indication and shelf presence
Private-label retailer exclusive	Compresses branded pricing
E-commerce multipack	Increases price transparency and switching
Pediatric-focused packaging	Competes on usability rather than active ingredient

A formulation patent could delay direct copying, but it would not prevent competing products using different excipients. The commercial moat is therefore likely to come from manufacturing cost, retailer relationships, taste acceptance, supply reliability, and brand recognition.

How strong is the patent estate for dye-free children’s loratadine?

The patent estate is likely weak for the broad product concept and potentially moderate for a narrowly defined formulation or delivery system.

Stronger protection

Protection is stronger when the applicant can demonstrate:

• A clear technical problem.
• A narrow but commercially important formulation.
• Reproducible stability data.
• A measurable taste or dosing benefit.
• A non-obvious relationship among pH, solvent, surfactant, and preservative.
• Manufacturing advantages that competitors cannot easily replicate.

Weaker protection

Protection is weaker when claims rely only on:

• Excluding colorants.
• Selecting common pediatric sweeteners.
• Using conventional fruit flavors.
• Combining known excipients without unexpected results.
• Repackaging a known loratadine concentration.
• Stating “free of” attributes without technical performance.

Trade-secret protection may be more practical for flavor composition, order of addition, mixing conditions, and process controls. Trade secrets do not prevent independent development, reverse engineering, or lawful use of a competing formulation.

What commercial opportunities exist for dye-free children’s loratadine?

The commercial opportunity is strongest in differentiated OTC channels rather than physician prescribing.

Retail pharmacy and mass retail

A dye-free liquid can occupy a premium or mid-tier position beside standard children’s allergy products. Retailers may favor a private-label version because the formulation is familiar to consumers and does not require a new therapeutic education campaign.

E-commerce

Online channels allow detailed filtering for dye-free, sugar-free, alcohol-free, and pediatric products. A product page can explain excipient attributes more effectively than a crowded shelf. Multipacks and subscription purchasing may support repeat demand during seasonal allergy periods.

Grocery and natural-product channels

Dye-free positioning may perform well with consumers who actively screen ingredient panels. Claims should remain factual and should not imply that the product is safer or more effective solely because it lacks color additives.

Travel and school use

Unit-dose sachets, stick packs, or small bottles could address portability. These formats may command a higher price, but package cost, dose accuracy, child-resistant requirements, and moisture protection must be controlled.

Licensing and private-label opportunities

The most viable licensing assets may include:

• A validated oral-liquid formulation.
• A scalable preservative and pH system.
• A taste-masking platform.
• A child-friendly dosing closure.
• A contract-manufacturing package with regulatory documentation.
• Retailer-exclusive rights for dye-free and sugar-free variants.

A licensing agreement should define ownership of formulation improvements, supplier changes, manufacturing deviations, regulatory submissions, and territorial rights.

What manufacturing and IP barriers affect launch?

Manufacturing barriers are manageable but can affect margin. The critical controls are loratadine dispersion, pH adjustment, solvent addition, preservative distribution, deaeration, filling accuracy, and container compatibility.

A commercial developer should protect:

• Raw-material specifications.
• Excipient supplier qualification.
• Flavor composition.
• Mixing order and shear conditions.
• In-process pH and assay controls.
• Cleaning validation for low-dose active ingredients.
• Bottle and closure compatibility.
• Stability-indicating analytical methods.
• Finished-product microbial limits.

The greatest operational risk is a product that passes initial release testing but develops precipitation, flavor drift, microbial growth, or dosing inconsistency during storage. Stability failures can damage retailer relationships more rapidly than a narrow patent dispute.

How does dye-free children’s loratadine compare with competing antihistamines?

Product category	Main advantage	Main weakness
Loratadine liquid	Familiar once-daily antihistamine; broad generic supply	Solubility and taste-management burden
Cetirizine liquid	Strong consumer recognition; established pediatric liquid category	May be associated with sedation in some users
Fexofenadine liquid	Non-sedating positioning	Different formulation and labeling considerations
Desloratadine liquid	Pediatric liquid positioning and branded history	Separate active ingredient and higher development or licensing complexity
Chewable loratadine	Lower packaging and liquid-stability burden	Requires adequate chewing ability and palatability
Orally disintegrating loratadine	Portable and water-free dosing	Higher manufacturing and taste-masking requirements

The commercial decision should be based on target age, dose volume, flavor acceptance, retail price, and channel availability. Dye-free positioning can apply across several antihistamines, so the attribute alone does not create durable differentiation.

Key Takeaways

• Dye-free children’s loratadine is primarily an OTC formulation and commercialization opportunity, not a molecule-exclusivity opportunity.
• Loratadine’s low water solubility makes solubilization, precipitation control, taste, and stability the central technical issues.
• The strongest product proposition combines dye-free status with sugar-free, alcohol-free, accurate dosing, or travel-friendly packaging.
• Pediatric excipients require exposure-based assessment, especially for propylene glycol, sorbitol, preservatives, sodium, and flavoring agents.
• Broad patents on a dye-free loratadine liquid would likely face substantial prior-art challenges.
• Narrow formulation, process, device, or packaging claims may have greater value than claims directed only to the absence of dyes.
• Generic and private-label entry risk is high because loratadine is a mature OTC active ingredient.
• A validated formulation, taste system, dosing device, and manufacturing package may be more commercially valuable than a broad patent claim.
• There is no biosimilar risk; competitive pressure comes from generic antihistamines and alternative dosage forms.
• Revenue exposure cannot be assessed at the company or brand level without a specified manufacturer, product, market, and sales base.

FAQs

Is dye-free children’s loratadine automatically safer than standard loratadine?

No. Removing color additives may address a consumer preference or a specific sensitivity concern, but overall product safety depends on the active ingredient, dose, excipients, impurities, microbiological quality, and labeling.

Can a dye-free loratadine liquid be preservative-free?

Yes, but a multidose preservative-free liquid creates a higher microbial-control burden. Unit-dose packaging or a dry powder for reconstitution may be more practical than a conventional multidose bottle.

Is sugar-free loratadine commercially better than dye-free loratadine?

Sugar-free positioning may reach a broader consumer segment, but it can create taste and gastrointestinal-tolerability tradeoffs. Combining sugar-free and dye-free claims may provide stronger shelf differentiation than either claim alone.

Can a company patent the absence of artificial dyes in loratadine syrup?

A claim based only on excluding dyes is likely vulnerable to prior-art and obviousness challenges. Patentability improves when the formulation includes a novel technical system with demonstrated stability, taste, dosing, or manufacturing benefits.

Does dye-free children’s loratadine require a new FDA approval?

Not necessarily. A compliant OTC product may qualify under the applicable OTC monograph framework. Products outside the monograph or with novel claims may require a different FDA submission or regulatory pathway.

References

1. U.S. Food and Drug Administration. (2020). Inactive ingredient database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download

2. U.S. Food and Drug Administration. (2016). Safety of inactive ingredients in pediatric drug products: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

3. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.